NCT04176562
Recruiting
Not Applicable
Prospective Study on Safety and Performance of Surgalign spINE Products
Xtant Medical12 sites in 3 countries5,000 target enrollmentJanuary 28, 2020
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Sacroiliac; Fusion
- Sponsor
- Xtant Medical
- Enrollment
- 5000
- Locations
- 12
- Primary Endpoint
- Intervention Rates
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This study is a prospective, multi-center, open label registry designed to collect real-world data on performance and safety data on RTI's spine products.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Candidate for RTI spine product.
- •Willing and able to consent to the study.
Exclusion Criteria
- •Patient who is, or is expected to be inaccessible for follow-up.
- •Patient meets any exclusion criteria required by local law (e.g. age, mental capacity, etc.).
- •Other concurrent medical or other condition (chronic or acute in nature) that in the opinion of the investigator may prevent participation or otherwise render patient ineligible for the study.
Outcomes
Primary Outcomes
Intervention Rates
Time Frame: 1 month, 3 months, 6 months, 12 months, and 24 months
Rates of reoperation and/or revision procedures at index level
Secondary Outcomes
- Disability (Cervical)(1 month, 3 months, 6 months, 12 months, and 24 months)
- Fusion(1 month, 3 months, 6 months, 12 months, and 24 months)
- Time to Intervention(1 month, 3 months, 6 months, 12 months, and 24 months)
- Radiographic Findings(1 month, 3 months, 6 months, 12 months, and 24 months)
- Adverse Events(1 month, 3 months, 6 months, 12 months, and 24 months)
- Disability (non-Cervical)(1 month, 3 months, 6 months, 12 months, and 24 months)
- Pain Change(1 month, 3 months, 6 months, 12 months, and 24 months)
Study Sites (12)
Loading locations...
Similar Trials
Unknown
Not Applicable
A Prospective, Single-arm, Multi-centre, Observational, Real World RegistryAngina PectorisNCT02901353Meril Life Sciences Pvt. Ltd.400
Terminated
Phase 2
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's DiseaseHuntington's DiseaseNCT02494778Prilenia248
Active, not recruiting
Phase 2
Open-Label Study of AG10 in Patients with CardiomyopathyAmyloid CardiomyopathyNCT03536767Eidos Therapeutics, a BridgeBio company55
Active, not recruiting
Not Applicable
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular DegenerationGeographic AtrophyNCT06161584Apellis Pharmaceuticals, Inc.300
Unknown
Phase 1
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell CarcinomaSuperficial Basal Cell CarcinomaNodular Basal Cell CarcinomaNCT05157763MediWound Ltd32